Abstract:Abstract Introduction Methadone treatment for opioid use disorder (OUD) reduces drug cravings and promotes abstinence, but sleep disturbances can negatively impact OUD recovery outcomes. Irregular sleep architecture and respiratory disturbance in outpatients administered methadone as medication for OUD (MOUD) are common, but inter-individual differences may be substantial. We investigated the magnitude and stability of inter-individual differences in sleep architecture and respiratory measures in outpatients in their first 90 days of MOUD treatment. Methods N=6 adults (42.5±10.4y, four females) enrolled in local MOUD programs participated in this research study. The daily methadone dose varied between participants (75.8±23.2mg, range 50-120mg). All participants reported past use of multiple substances; four reported current mental health disorders; and four reported chronic pain. As part of the study, participants underwent two consecutive nights of cardiorespiratory PSG, with lights off at 21:49 on average (range 21:17-22:16) on both nights. Sleep stages and apnea-hypopnea index (AHI) were analyzed for systematic inter-individual differences using variance components analysis. The stability of inter-individual differences was quantified with the intraclass correlation coefficient (ICC, ranging from 0 to 1 for negligible to complete stability). Results On night one, mean±SD was 441.9±21.1min for total sleep time (TST), 9.0±5.2min for sleep latency (SL), 35.3±22.4min for wakefulness after sleep onset (WASO), 28.8±26.6min for N1, 220.8±58.6min for N2, 114.0±77.2min for N3, and 78.3±65.6min for REM. AHI scores were 16.4±9.1, indicating moderate sleep apnea on average. Compared to similarly aged healthy adults, N1 was low, and TST, WASO, N2, REM, and AHI were high. Stability was significant and substantial for N1, N2, REM, and AHI (ICC≥0.68, F≥5.19, P< 0.05). Conclusion Despite small sample size, we found substantial, stable inter-individual differences in N1, N2, REM, and AHI, whereas TST, SL, WASO, and N3 did not reach statistical significance. Varying methadone doses, prior substance use, physical and mental health, chronic pain, and (epi)genetic predisposition may partially account for these inter-individual differences. Our PSG data were collected in-laboratory, not naturalistically; results should be interpreted accordingly. Given the substantial, stable inter-individual differences in sleep architecture, a personalized approach to sleep management may be crucial to help improve OUD recovery outcomes. Support (if any) WSU ORAP and HSCL

0911 Characterizing Sleep, Pain, and Opioid Craving in People with Chronic Low Back Pain on Long Term Opioid Therapy

Neuropsychology of chronic back pain managed with long-term opioid use

0986 Inter-Individual Differences in Sleep Architecture of Patients Receiving Methadone for Opioid Use Disorder

Sleep behavior traits and associations with opioid-related adverse events: a cohort study

Long-Term Opioid Use and Emotional, Cognitive, and Sensorimotor Function in Chronic Back Pain

0845 Individuals with Persistent Low Back Pain Have Less Time in Deep Sleep Stage than Asymptomatic Controls

Sleep-related impairment among people who use opioids: The critical role of structural vulnerability

Psychosocial Factors Associated with Sleep Quality and Duration Among Older Adults with Chronic Pain

0685 Opioid Treatment of Patients with Painful versus Painless Restless Legs Syndrome

Predictive factors for sleep apnoea in patients on opioids for chronic pain

The relationship of pain intensity and opioid craving with delayed methadone dose: A preliminary study of individuals with opioid use disorder

Opioid dose risk, clinician and patient characteristics, and adherence to opioid prescribing recommendations in chronic non-cancer pain

A Longitudinal Study of the Association of Opioid Use with Change in Pain Interference and Functional Limitations in a Nationally Representative Cohort of Adults with Osteoarthritis in the United States

Clinical Phenotypes Supporting the Relationship Between Sleep Disturbance and Impairment of Placebo Effects

Developing a novel treatment for patients with chronic pain and Opioid User Disorder

Spontaneous oxycodone withdrawal disrupts sleep, circadian, and electrophysiological dynamics in rats

Abnormal Pain Response in Pain-Sensitive Opiate Addicts after Prolonged Abstinence Predicts Increased Drug Craving

Chronic Sleep Deprivation Blocks Voluntary Morphine Consumption but Not Conditioned Place Preference in Mice

Elevated pain sensitivity is associated with reduced REM sleep in females with comorbid temporomandibular disorder and insomnia

The bidirectional relationship between sleep complaints and pain: Analysis of data from a randomized trial.

Pathogenesis of sleep disordered breathing in the setting of opioid use: A multiple mediation analysis using physiology